Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of BL-M07D1 versus investigator's choice therapy in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma after failure of first-line anti-HER2 therapy
CTR20253456Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of BL-M07D1 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Biokin Pharmaceutical. Started Oct 2025; status: active.
02
Drugs
BL-M07D1
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20253456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253456.